| 摘要 |
The invention is directed to novel oxo-amino-sulfonyl-azapanes. Specifically, the invention is directed to compounds according to Formula (I); wherein R1, R2, and R3 are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are protease inhibitors and can be useful in treating conditions in which the pathology may be therapeutically modified by inhibiting a cysteine or serine protease of the papain superfamily, particularly cathepsin K. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of treatment for conditions characterized by bone loss including osteoporosis and gingival diseases, and by excessive cartilage or matrix degradation including osteoarthritis and rheumatoid arthritis using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. The invention is also directed to methods of treatment for certain parasitic diseases such as malaria using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. |
